SCHEMBL12874713

SCHEMBL12874713

CNc1cncc(-c2ccc(Oc3ccc(O)cc3)cc2)c1C(=N)N

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.35
▸ ESR2 Q92731 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ESR1 P03372 1/20 0.35
▸ RPS6KA3 P51812 1/20 0.35
▸ LTA4H P09960 3/20 0.34
▸ ST14 Q9Y5Y6 2/20 0.34
▸ F2 P00734 1/20 0.34
▸ PLAU P00749 1/20 0.34
▸ PARP10 Q53GL7 1/20 0.34
▸ LCK P06239 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ TEK Q02763 1/20 0.34
▸ BTK Q06187 2/20 0.34
▸ USP7 Q93009 2/20 0.32
▸ NR1H2 P55055 1/20 0.32
▸ BAX Q07812 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ LMNA P02545 1/20 0.31
▸ HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18800739 0.82 MEN1 (0.39) KMT2AESR2MEN1ESR1RPS6KA3
SCHEMBL18800606 0.73 NQO2 (0.43) KMT2ARPS6KA3LTA4HST14F2
SCHEMBL12874718 0.71 BTK (0.43) KMT2AMEN1LTA4HPLAUBTK
SCHEMBL18800557 0.68 PRSS1 (0.45) KMT2ARPS6KA3HTT
SCHEMBL18800626 0.68 SMN1; SMN2 (0.48) KMT2AMEN1F2BTKNPSR1
SCHEMBL30047702 0.64 DGAT1 (0.53) KMT2AESR2MEN1ESR1RPS6KA3
SCHEMBL18780266 0.64 BTK (0.53) KMT2AMEN1LTA4HBTKNR1H2
SCHEMBL2905032 0.63 ESR2 (0.56) KMT2AESR2MEN1ESR1LTA4H
SCHEMBL19286912 0.63 ST14 (0.83) KMT2AESR2MEN1ESR1ST14
SCHEMBL18800873 0.62 SCN5A (0.37) KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011019780-A1 AZAINDAZOLES AS BTK KINASE MODULATORS AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2011-02-17 — — WO disclosed
Send feedback